{"id":"f-18-flornaptitril","safety":{"commonSideEffects":[{"rate":"null","effect":"Palpitations"},{"rate":"null","effect":"Tachycardia"},{"rate":"null","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL3545253","moleculeType":"Small molecule","molecularWeight":"262.28"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Flornaptitril acts as a beta-2 adrenergic receptor agonist, which means it stimulates the beta-2 receptors in the body. This stimulation leads to an increase in heart rate and contractility, making it a potential treatment for conditions such as atrial fibrillation.","oneSentence":"Flornaptitril is a beta-2 adrenergic receptor agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:09.813Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"[F-18]Flornaptitril","genericName":"[F-18]Flornaptitril","companyName":"CereMark Pharma, LLC","companyId":"ceremark-pharma-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Flornaptitril is a beta-2 adrenergic receptor agonist. Used for Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}